Beta thalassemia is caused by mutations in the HBB gene, which provides the instructions your body needs to make a protein called beta-globin. Beta-globin is one of two building blocks of hemoglobin, the molecule inside red blood cells that carries oxygen. Hundreds of different mutations in this single gene have been identified, and they all share one outcome: your body either makes too little beta-globin or none at all.
The Gene Behind It
Every person inherits two copies of the HBB gene, one from each parent. When one or both copies carry a mutation, the production of beta-globin drops. The type of mutation determines how much production is lost. Some mutations reduce output but don’t stop it entirely. These are called beta-plus variants, and they tend to result from changes in the gene’s regulatory regions, the stretches of DNA that control how efficiently the gene is read. Other mutations shut down beta-globin production completely. These beta-zero variants typically involve more disruptive changes to the gene’s coding sequence, like inserting or deleting a piece of DNA so the instructions no longer make sense.
What matters most for severity is the combination of variants a person inherits. Someone who gets two beta-zero copies produces virtually no beta-globin and develops the most severe form of the disease. Someone with two beta-plus copies, or one of each, generally has a milder course. And someone who inherits just one faulty copy alongside one normal copy is a carrier, often with no symptoms at all.
How It Disrupts Red Blood Cells
Hemoglobin is built from two alpha-globin chains and two beta-globin chains, paired together in a precise ratio. When beta-globin production falls short, the alpha chains have no partners. These unpaired alpha chains are unstable and toxic to developing red blood cells.
Research has shown exactly what happens next. Unpaired alpha chains generate significantly higher levels of damaging molecules, including hydrogen peroxide and other oxidants, inside red blood cells. They bind to the cell membrane, degrading key structural proteins that give the cell its shape and flexibility. They also deposit iron and a compound called heme directly onto the membrane, accelerating further damage. In experiments where purified alpha chains were loaded into normal red blood cells, the cells’ built-in antioxidant defense dropped by nearly 40%, and their vulnerability to oxidative damage increased dramatically.
The result is that many developing red blood cells are destroyed before they ever leave the bone marrow, a process called ineffective erythropoiesis. The body responds by ramping up red blood cell production, expanding the bone marrow to try to compensate. But most of these new cells are also defective. The ones that do make it into the bloodstream are smaller and more fragile than normal, carrying less hemoglobin and living shorter lives. This is why beta thalassemia causes chronic anemia.
Inheritance and Risk
Beta thalassemia follows an autosomal recessive pattern, meaning the gene sits on a non-sex chromosome and a child needs to inherit a faulty copy from each parent to develop significant disease. When both parents are carriers (each carrying one mutated and one normal copy), every pregnancy has a 25% chance of producing a child with two faulty copies, a 50% chance of producing another carrier, and a 25% chance of producing a child with two normal copies.
Carriers themselves are usually clinically asymptomatic. They may have slightly smaller red blood cells and mildly lower hemoglobin, but most never know they carry the trait unless they’re tested. This is precisely why carrier screening before or during pregnancy is so important in populations where the gene is common.
Three Levels of Severity
The clinical picture of beta thalassemia ranges from invisible to life-threatening, depending on how much beta-globin the body can still produce.
Beta-thalassemia minor is the carrier state. People with one normal and one mutated gene copy typically have no symptoms or only mild anemia. Their hemoglobin levels usually fall between 9.5 and 12.5 g/dL, slightly below the normal range. It’s often discovered incidentally on a routine blood test showing smaller-than-average red blood cells.
Beta-thalassemia intermedia falls in the middle. These individuals have two mutated copies, but at least one is a beta-plus variant that still allows some beta-globin production. Hemoglobin levels generally range from 7 to 10 g/dL. The age at which symptoms appear varies widely, and while the anemia is significant, it doesn’t require regular transfusions in early childhood.
Beta-thalassemia major (also called Cooley’s anemia) is the most severe form. Children with two beta-zero variants produce virtually no normal adult hemoglobin. They typically present between 6 and 24 months of age with pallor, poor weight gain, stunted growth, mild jaundice, and an enlarged liver and spleen. Hemoglobin drops below 7 g/dL. These children require regular blood transfusions to survive, often every two to four weeks for life.
The Iron Overload Problem
One of the most consequential complications of beta thalassemia is iron overload, and it has two separate causes. The first is transfusion-related. Each unit of transfused red blood cells delivers roughly 250 mg of iron, but the body can only excrete about 1 mg of iron per day. A patient receiving 25 units per year accumulates approximately 5 grams of excess iron annually. Over years, that iron deposits in the heart, liver, and hormone-producing glands, causing serious organ damage if not managed with iron-removal therapy.
The second cause affects even patients who don’t receive transfusions. Ineffective erythropoiesis sends a misleading signal to the gut, suppressing a hormone called hepcidin that normally limits iron absorption from food. With hepcidin levels paradoxically low, the intestines absorb far more iron than the body needs. This mechanism is especially prominent in beta-thalassemia intermedia, where patients may develop significant iron overload purely from increased dietary absorption.
Where Beta Thalassemia Is Most Common
About 3% of the world’s population carries a beta-thalassemia mutation, but the gene is not evenly distributed. The highest carrier rates cluster along what researchers call the “thalassemia belt,” a band stretching from the Mediterranean through the Middle East, South Asia, and into Southeast Asia. Cyprus has a carrier rate of about 14%, Sardinia around 12%, and parts of Southeast Asia are similarly high. More than 80% of people living with hemoglobin disorders are in developing countries.
This geographic concentration is not random. It closely mirrors the historical distribution of malaria. Carrying one copy of a beta-thalassemia mutation appears to offer some protection against severe malaria, giving carriers a survival advantage in regions where the disease was endemic. Over thousands of years, this selective pressure pushed the mutation to higher frequencies in those populations, even though inheriting two copies causes serious illness.
How It’s Detected
Diagnosis typically involves a blood test called hemoglobin electrophoresis, which separates the different types of hemoglobin in a sample. In a healthy adult, about 96% to 98% of hemoglobin is the normal adult form (HbA), with 2% to 3% of a minor variant called HbA2, and less than 1% of fetal hemoglobin (HbF). In beta-thalassemia major, HbA drops to near zero and fetal hemoglobin can rise to 95%, as the body reverts to producing the type of hemoglobin it used before birth. In carriers, HbA2 rises above 4%, which is often the key clue on a lab report.
For couples who are both carriers, prenatal testing can determine whether a pregnancy is affected. The most widely used method is chorionic villus sampling, performed around weeks 10 to 12 of pregnancy. Fetal DNA is then analyzed for the specific mutations carried by the parents. This allows families to know early in the pregnancy whether the child will have thalassemia major, be a carrier, or be unaffected.